Confira Laboratories Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 04-01-2025
- Paid Up Capital ₹ 9.33 Cr
as on 04-01-2025
- Company Age 6 Year, 5 Days
- Last Filing with ROC 31 Mar 2024
- Revenue -81.67%
(FY 2021)
- Profit -97.60%
(FY 2021)
- Ebitda -92.04%
(FY 2021)
- Net Worth -478.35%
(FY 2021)
- Total Assets 150.71%
(FY 2021)
About Confira Laboratories
The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 9.33 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mehul Shah, Niti Shah, and Niloni Shah serve as directors at the Company.
- CIN/LLPIN
U24290MH2019PTC319509
- Company No.
319509
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Confira Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niloni Shah  | Managing Director | 09-May-2023 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mehul Shah | Director | 14-Jan-2019 | Current |
| Niti Shah | Director | 14-Jan-2019 | Current |
Financial Performance of Confira Laboratories.
Confira Laboratories Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 81.67% decrease. The company also saw a substantial fall in profitability, with a 97.6% decrease in profit. The company's net worth observed a substantial decline by a decrease of 478.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Confira Laboratories?
In 2022, Confira Laboratories had a promoter holding of 97.59% and a public holding of 2.41%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ciens Investment Advisory Services Private LimitedActive 24 years 11 months
Mehul Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Confira Laboratories?
Unlock and access historical data on people associated with Confira Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Confira Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Confira Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
